Stereotaxis (NYSEAMERICAN:STXS) Trading 4.4% Higher

Stereotaxis, Inc. (NYSEAMERICAN:STXS)’s share price was up 4.4% on Thursday . The company traded as high as $2.68 and last traded at $2.62. Approximately 214,107 shares were traded during mid-day trading, a decline of 19% from the average daily volume of 264,972 shares. The stock had previously closed at $2.51.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Roth Mkm reiterated a “buy” rating and set a $5.00 price objective on shares of Stereotaxis in a research note on Tuesday, March 5th. Lake Street Capital increased their price target on shares of Stereotaxis from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th.

Stereotaxis Trading Up 4.4 %

The firm has a market cap of $215.18 million, a PE ratio of -9.36 and a beta of 1.35.

Stereotaxis (NYSEAMERICAN:STXS) last posted its quarterly earnings data on Monday, March 4th. The company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). Stereotaxis had a negative net margin of 77.37% and a negative return on equity of 103.37%. The company had revenue of $4.57 million during the quarter, compared to the consensus estimate of $7.55 million. On average, analysts forecast that Stereotaxis, Inc. will post -0.23 EPS for the current year.

Hedge Funds Weigh In On Stereotaxis

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in Stereotaxis during the fourth quarter worth $26,000. Barclays PLC acquired a new position in Stereotaxis during the third quarter worth about $35,000. Marshall Wace LLP acquired a new position in Stereotaxis during the fourth quarter worth about $36,000. Virtu Financial LLC acquired a new position in shares of Stereotaxis in the 4th quarter valued at $37,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Stereotaxis in the 1st quarter valued at $44,000. Hedge funds and other institutional investors own 45.35% of the company’s stock.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.